We are therefore cautious in making further derivations of the study group into smaller subgroups (e.g. separate analysis of scalp melanoma and other head and neck skin regions, or separate comparison of the effect of PD1 versus CTLA4 inhibitors). The gene discussed is CTLA4; the disease is melanoma.